Clinical Trial

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
Protocol Amendment History 59 amendments
This ClinicalTrials.gov record has been amended 59 times since 2020-11-16; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2025-12-01
Status change: Not Yet Recruiting → Recruiting 2021-09-08
Trial Details
NCT Number NCT04632953
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Enrollment 150 participants
Start Date 2021-11-30
Primary Completion 2035-12 (estimated)
Study Completion 2035-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-03